Delayed Nasdaq  -  04:00 2022-08-11 pm EDT
0.8000 USD   +9.59%
07/25Certain Series C Preferred Stock of BioSig Technologies, Inc. are subject to a Lock-Up Agreement Ending on 25-JUL-2022.
07/25Certain Restricted Stock Units of BioSig Technologies, Inc. are subject to a Lock-Up Agreement Ending on 25-JUL-2022.
07/25Certain Common Stock of BioSig Technologies, Inc. are subject to a Lock-Up Agreement Ending on 25-JUL-2022.
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

BioSig Technologies : ViralClear Pharmaceuticals partners with Albany Molecular Research Inc. on the manufacture of merimepodib active pharmaceutical ingredient development for the potential treatment of COVID-19

07/08/2020 | 01:13pm EDT

Westport, CT, July 08, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it is partnering with Albany Molecular Research Inc., (AMRI), a leading global contract research, development and manufacturing organization (CDMO), for support in undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a standalone treatment or in combination with other anti-viral agents or immune modulators.

“As part of our ongoing development and commercialization strategy we are delighted to be working with AMRI as our second US-based active pharmaceutical ingredient (API) supplier. The rapid transfer, scale up and validation of merimepodib API manufacture is key to our future supply chain and commercialization strategy,” commented Steve King, Chief Operating Officer, ViralClear. He continued, “ViralClear is committed to using US-based CDMOs for the development and commercialization of merimepodib.”

“AMRI is proud to partner with ViralClear in this vital effort of seeking a potential treatment for COVID-19,” said Christopher Conway, President, AMRI. “Our team is committed to applying the expertise and experience we’re renowned for to help combat this complex global health challenge.”

About BioSig Technologies

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (

The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

About Viral Clear Pharmaceuticals, Inc. and Merimepodib (MMPD)

BioSig Technologies, Inc.’s (Nasdaq: BSGM) subsidiary, ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19. Merimepodib is intended to be orally administered, and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures. Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5 in phase 2) with over 400 subjects and patients and an extensive preclinical safety package was completed. A manuscript titled, “The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue Remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro”, was submitted to an online peer-reviewed life sciences journal. This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author. This article highlights pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch.

About AMRI

AMRIa contract research development and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. AMRI’s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in discovery, development, analytical services, and API and drug product manufacturing.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
203-409-5444, x133

Kerry Hutchings


Source: BioSig Technologies, Inc.

2020 GlobeNewswire, Inc., source Press Releases

07/25Certain Series C Preferred Stock of BioSig Technologies, Inc. are subject to a Lock-Up ..
07/25Certain Restricted Stock Units of BioSig Technologies, Inc. are subject to a Lock-Up Ag..
07/25Certain Common Stock of BioSig Technologies, Inc. are subject to a Lock-Up Agreement En..
07/25Certain Options of BioSig Technologies, Inc. are subject to a Lock-Up Agreement Ending ..
07/25Certain Warrants of BioSig Technologies, Inc. are subject to a Lock-Up Agreement Ending..
07/21BioSig Announces Physician-Initiated Research Protocol at The Kansas City Heart Rhythm ..
07/15BIOSIG TECHNOLOGIES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
07/07BIOSIG TECHNOLOGIES : Announces Purchase Agreement with Kansas City Heart Rhythm Institute..
07/07BIOSIG TECHNOLOGIES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
07/07BioSig Technologies Enters Deal to Provide Medical Technology to Kansas City Heart Inst..
More news
Financials (USD)
Sales 2022 1,44 M - -
Net income 2022 -29,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,07x
Yield 2022 -
Capitalization 35,2 M 35,2 M -
Capi. / Sales 2022 24,4x
Capi. / Sales 2023 4,53x
Nbr of Employees 50
Free-Float 89,2%
Duration : Period :
BioSig Technologies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOSIG TECHNOLOGIES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,80 $
Average target price 5,00 $
Spread / Average Target 525%
EPS Revisions
Managers and Directors
Kenneth L. Londoner Executive Chairman & Chief Executive Officer
Steven Chaussy Chief Financial Officer
Budimir S. Drakulic Chief Scientist
Zachary Koch Clinical Director
John Sieckhaus Chief Operating Officer
Sector and Competitors